Genocea Herpes Funding for herpes cure clinical trials

Genocea receives $30 million funding for herpes vaccine in clinical trials

A vaccine or even a cure for herpes gets closer as Genocea Biosciences raises $30 million for research.  The biotech start-up has a proprietary technology to identify and use T-cell antigens to target large pathogens like HSV-2, pneumococcus, chlamydia and malaria, reports MedCityNews. We were first excited when we heard about Genocea’s clinical trials for…

Herpes HSV Vaccine Clinical Trial needs Volunteers,

Herpes cure? New clinical trial for HSV2 vaccine needs volunteers for research testing

Could a cure for Herpes be on its way?  A promising new clinical trial for a HSV2 vaccine  just opened up for human research testing and is looking for volunteers. Genocea Biosciences – Our lead candidate in HSV-2 is GEN-003, a first-in-class, protein subunit, therapeutic T cell vaccine designed to reduce the duration and severity…

Herpes Type HSV1 HSV2

Herpes Simplex Type breakdown. The difference between HSV1 and HSV2

The Herpes Simplex Virus (HSV) can be broken down into two different types. HSV-1 is typically oral herpes where HSV-2 is almost always in the genital region. Without going into all the mind numbing medical details, we figured that we would break it down and explain what the difference is. Both types share some similarities,…